210 related articles for article (PubMed ID: 37386469)
1. Physician- and patient-reported perspectives on myasthenia gravis in Europe: a real-world survey.
Mahic M; Bozorg A; DeCourcy J; Golden K; Gibson G; Taylor C; Scowcroft A
Orphanet J Rare Dis; 2023 Jun; 18(1):169. PubMed ID: 37386469
[TBL] [Abstract][Full Text] [Related]
2. Physician-Reported Perspectives on Myasthenia Gravis in the United States: A Real-World Survey.
Mahic M; Bozorg AM; DeCourcy JJ; Golden KJ; Gibson GA; Taylor CF; Ting A; Story TJ; Scowcroft A
Neurol Ther; 2022 Dec; 11(4):1535-1551. PubMed ID: 35859033
[TBL] [Abstract][Full Text] [Related]
3. Patient-reportedimpact of myasthenia gravis in the real world: protocol for a digital observational study (MyRealWorld MG).
Berrih-Aknin S; Claeys KG; Law N; Mantegazza R; Murai H; Saccà F; Dewilde S; Janssen MF; Bagshaw E; Kousoulakou H; Larkin M; Beauchamp J; Leighton T; Paci S
BMJ Open; 2021 Jul; 11(7):e048198. PubMed ID: 34285010
[TBL] [Abstract][Full Text] [Related]
4. Idiopathic pulmonary fibrosis: Physician and patient perspectives on the pathway to care from symptom recognition to diagnosis and disease burden.
Lancaster L; Bonella F; Inoue Y; Cottin V; Siddall J; Small M; Langley J
Respirology; 2022 Jan; 27(1):66-75. PubMed ID: 34611971
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG.
Dewilde S; Philips G; Paci S; Beauchamp J; Chiroli S; Quinn C; Day L; Larkin M; Palace J; Berrih-Aknin S; Claeys KG; Muppidi S; Mantegazza R; Saccà F; Meisel A; Bassez G; Murai H; Janssen MF
BMJ Open; 2023 Jan; 13(1):e066445. PubMed ID: 36720569
[TBL] [Abstract][Full Text] [Related]
6. Physician- and Patient-Reported Severity and Quality of Life Impact of Alopecia Areata: Results from a Real-World Survey in Five European Countries.
Vañó-Galván S; Blume-Peytavi U; Farrant P; Reygagne P; Johansson E; Reed C; Marwaha S; Durand F; Piraccini BM
Dermatol Ther (Heidelb); 2023 Dec; 13(12):3121-3135. PubMed ID: 37889388
[TBL] [Abstract][Full Text] [Related]
7. Acetylcholinesterase inhibitor treatment for myasthenia gravis.
Mehndiratta MM; Pandey S; Kuntzer T
Cochrane Database Syst Rev; 2011 Feb; (2):CD006986. PubMed ID: 21328290
[TBL] [Abstract][Full Text] [Related]
8. Characteristics, clinical outcomes and patient-reported outcomes of patients with ulcerative colitis receiving tofacitinib: a real-world survey in the United States and five European countries.
Armuzzi A; Hart A; Cappelleri JC; Mammar N; Hur P; Hoskin B; Hennessy F; Milligan G; Dignass A
BMC Gastroenterol; 2023 Jan; 23(1):17. PubMed ID: 36658481
[TBL] [Abstract][Full Text] [Related]
9. The impact of myasthenia gravis severity on work and daily activities.
Pesa J; Choudhry Z; de Courcy J; Barlow S; Chatterton E; Thomas O; Gibson G; Hahn B; Govindarajan R
Muscle Nerve; 2024 Apr; 69(4):428-439. PubMed ID: 38348518
[TBL] [Abstract][Full Text] [Related]
10. Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data.
Pisc J; Ting A; Skornicki M; Sinno O; Lee E
J Comp Eff Res; 2024 Jan; 13(1):e230108. PubMed ID: 38099519
[No Abstract] [Full Text] [Related]
11. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
[TBL] [Abstract][Full Text] [Related]
12. Impact of osteoarthritis disease severity on treatment patterns and healthcare resource use: analysis of real-world data.
Conaghan PG; Abraham L; Viktrup L; Cappelleri JC; Beck C; Bushmakin AG; Berry M; Jackson J
Scand J Rheumatol; 2023 Jul; 52(4):353-363. PubMed ID: 35587006
[TBL] [Abstract][Full Text] [Related]
13. Patient-reported impact of myasthenia gravis in the real world: findings from a digital observational survey-based study (MyRealWorld MG).
Berrih-Aknin S; Palace J; Meisel A; Claeys KG; Muppidi S; Saccà F; Amini F; Larkin M; Quinn C; Beauchamp J; Philips G; De Ruyck F; Ramirez J; Paci S
BMJ Open; 2023 May; 13(5):e068104. PubMed ID: 37169499
[TBL] [Abstract][Full Text] [Related]
14. Medical and surgical treatment for ocular myasthenia.
Benatar M; Kaminski H
Cochrane Database Syst Rev; 2006 Apr; (2):CD005081. PubMed ID: 16625623
[TBL] [Abstract][Full Text] [Related]
15. The natural history and ophthalmic involvement in childhood myasthenia gravis at the hospital for sick children.
Mullaney P; Vajsar J; Smith R; Buncic JR
Ophthalmology; 2000 Mar; 107(3):504-10. PubMed ID: 10711889
[TBL] [Abstract][Full Text] [Related]
16. Impact of Dementia-Related Behavioral Symptoms on Healthcare Resource Use and Caregiver Burden: Real-World Data from Europe and the United States.
Chekani F; Pike J; Jones E; Husbands J; Khandker RK
J Alzheimers Dis; 2021; 81(4):1567-1578. PubMed ID: 34057080
[TBL] [Abstract][Full Text] [Related]
17. Real-World Treatment Patterns in Metastatic Castration-Resistant Prostate Cancer Across Europe (France, Germany, Italy, Spain, and the United Kingdom) and Japan.
Leith A; Kim J; Ribbands A; Clayton E; Yang L; Ghate SR
Adv Ther; 2022 May; 39(5):2236-2255. PubMed ID: 35316501
[TBL] [Abstract][Full Text] [Related]
18. A real-world analysis of factors associated with high healthcare resource utilization and costs in patients with myasthenia gravis receiving second-line treatment.
Ting A; Story T; Lecomte C; Estrin A; Syed S; Lee E
J Neurol Sci; 2023 Feb; 445():120531. PubMed ID: 36634582
[TBL] [Abstract][Full Text] [Related]
19. The history of acetylcholinesterase inhibitors in the treatment of myasthenia gravis.
Katz NK; Barohn RJ
Neuropharmacology; 2021 Jan; 182():108303. PubMed ID: 32918950
[TBL] [Abstract][Full Text] [Related]
20. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF; Bril V; Vu T; Karam C; Peric S; Margania T; Murai H; Bilinska M; Shakarishvili R; Smilowski M; Guglietta A; Ulrichts P; Vangeneugden T; Utsugisawa K; Verschuuren J; Mantegazza R;
Lancet Neurol; 2021 Jul; 20(7):526-536. PubMed ID: 34146511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
